Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1964 1
1976 1
1977 1
1978 1
1979 2
1982 4
1984 2
1986 2
1988 2
1992 1
1993 1
1994 2
1995 2
1996 2
1997 2
1998 1
1999 1
2000 1
2001 1
2002 1
2003 2
2004 2
2005 2
2006 2
2007 1
2008 2
2009 5
2010 7
2011 8
2012 5
2013 4
2014 7
2015 8
2016 8
2017 17
2018 12
2019 20
2020 22
2021 22
2022 18
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Jenniree
Page 1
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A, Sachdeva Y, Mittal S, Osiyemi O, Skarbinski J, Juneja K, Hyland RH, Osinusi A, Chen S, Camus G, Abdelghany M, Davies S, Behenna-Renton N, Duff F, Marty FM, Katz MJ, Ginde AA, Brown SM, Schiffer JT, Hill JA; GS-US-540-9012 (PINETREE) Investigators. Gottlieb RL, et al. N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22. N Engl J Med. 2022. PMID: 34937145 Free PMC article. Clinical Trial.
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, Herrera-Ramos E, Ruíz-Hernández J, Borderías L, Horcajada J, González-Quevedo N, Rajas O, Briones M, Rodríguez de Castro F, Rodríguez Gallego C, Esen F, Orhun G, Ergin Ozcan P, Senturk E, Ugur Yilmaz C, Orhan N, Arican N, Kaya M, Kucukerden M, Giris M, Akcan U, Bilgic Gazioglu S, Tuzun E, Riff R, Naamani O, Douvdevani A, Takegawa R, Yoshida H, Hirose T, Yamamoto N, Hagiya H, Ojima M, Akeda Y, Tasaki O, Tomono K, Shimazu T, Ono S, Kubo T, Suda S, Ueno T, Ikeda T, Hirose T, Ogura H, Takahashi H, Ojima M, Kang J, Nakamura Y, Kojima T, Shimazu T, Ikeda T, Suda S, Izutani Y, Ueno T, Ono S, Taniguchi T, O M, Dinter C, Lotz J, Eilers B, Wissmann C, Lott R, Meili MM, Schuetz PS, Hawa H, Sharshir M, Aburageila M, Salahuddin N, Chantziara V, Georgiou S, Tsimogianni A, Alexandropoulos P, Vassi A, Lagiou F, Valta M, Micha G, Chinou E, Michaloudis G, Kodaira A, Ikeda T, Ono S, Ueno T, Suda S, Izutani Y, Imaizumi H, De la Torre-Prados MV, Garcia-De la Torre A, Enguix-Armada A, Puerto-Morlan A, Perez-Valero V, Garcia-Alcantara A, Bolton N, Dudziak J, Bonney S, Tridente A, Nee P, Nicolaes G, Wiewel M, Schultz M, Wildhag… See abstract for full author list ➔ Bateman RM, et al. Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Crit Care. 2016. PMID: 27885969 Free PMC article.
Routsi, C. Katsenos, I. Tsangaris, I. Pneumatikos, G. Vlachogiannis, V. Theodorou, A. Prekates, E. Antypa, V. Koulouras, N. Kapravelos, C. ...Hoste P173 - The use of 6 % HES solution do not reduce total fluid requirement in the therapy of patients with burn shock …
Routsi, C. Katsenos, I. Tsangaris, I. Pneumatikos, G. Vlachogiannis, V. Theodorou, A. Prekates, E. Antypa, V. Koulouras, N. Ka …
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L; EXCEED Study Group. McInnes IB, et al. Lancet. 2020 May 9;395(10235):1496-1505. doi: 10.1016/S0140-6736(20)30564-X. Lancet. 2020. PMID: 32386593 Clinical Trial.
De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias.
Helbig KL, Lauerer RJ, Bahr JC, Souza IA, Myers CT, Uysal B, Schwarz N, Gandini MA, Huang S, Keren B, Mignot C, Afenjar A, Billette de Villemeur T, Héron D, Nava C, Valence S, Buratti J, Fagerberg CR, Soerensen KP, Kibaek M, Kamsteeg EJ, Koolen DA, Gunning B, Schelhaas HJ, Kruer MC, Fox J, Bakhtiari S, Jarrar R, Padilla-Lopez S, Lindstrom K, Jin SC, Zeng X, Bilguvar K, Papavasileiou A, Xing Q, Zhu C, Boysen K, Vairo F, Lanpher BC, Klee EW, Tillema JM, Payne ET, Cousin MA, Kruisselbrink TM, Wick MJ, Baker J, Haan E, Smith N, Sadeghpour A, Davis EE, Katsanis N; Task Force for Neonatal Genomics; Corbett MA, MacLennan AH, Gecz J, Biskup S, Goldmann E, Rodan LH, Kichula E, Segal E, Jackson KE, Asamoah A, Dimmock D, McCarrier J, Botto LD, Filloux F, Tvrdik T, Cascino GD, Klingerman S, Neumann C, Wang R, Jacobsen JC, Nolan MA, Snell RG, Lehnert K, Sadleir LG, Anderlid BM, Kvarnung M, Guerrini R, Friez MJ, Lyons MJ, Leonhard J, Kringlen G, Casas K, El Achkar CM, Smith LA, Rotenberg A, Poduri A, Sanchis-Juan A, Carss KJ, Rankin J, Zeman A, Raymond FL, Blyth M, Kerr B, Ruiz K, Urquhart J, Hughes I, Banka S; Deciphering Developmental Disorders Study; Hedrich UBS, Scheffer IE, Helbig I, Zampo… See abstract for full author list ➔ Helbig KL, et al. Am J Hum Genet. 2018 Nov 1;103(5):666-678. doi: 10.1016/j.ajhg.2018.09.006. Epub 2018 Oct 18. Am J Hum Genet. 2018. PMID: 30343943 Free PMC article.
CACNA1E is highly expressed in the central nervous system and encodes the alpha(1)-subunit of the voltage-gated Ca(V)2.3 channel, which conducts high voltage-activated R-type calcium currents that initiate synaptic transmission. ...Most of the 14, partially recurring, vari …
CACNA1E is highly expressed in the central nervous system and encodes the alpha(1)-subunit of the voltage-gated Ca(V)2.3 channel, whi …
Extracorporeal Membrane Oxygenation for Respiratory Failure.
Quintel M, Bartlett RH, Grocott MPW, Combes A, Ranieri MV, Baiocchi M, Nava S, Brodie D, Camporota L, Vasques F, Busana M, Marini JJ, Gattinoni L. Quintel M, et al. Anesthesiology. 2020 May;132(5):1257-1276. doi: 10.1097/ALN.0000000000003221. Anesthesiology. 2020. PMID: 32149776 Free article. Review.
Non-invasive neurally adjusted ventilatory assist in preterm infants with RDS: effect of changing NAVA levels.
Lefevere J, Van Delft B, Vervoort M, Cools W, Cools F. Lefevere J, et al. Eur J Pediatr. 2022 Feb;181(2):701-707. doi: 10.1007/s00431-021-04244-3. Epub 2021 Sep 17. Eur J Pediatr. 2022. PMID: 34533644 Free PMC article.
Following a predefined titration protocol, NAVA levels were progressively increased starting from a level of 0.5 cmH(2)O/V and with increments of 0.5 cmH(2)O/V every 3 min, up to a maximum level of 4.0 cmH(2)O/V. ...The breakpoint was on average (SD) a …
Following a predefined titration protocol, NAVA levels were progressively increased starting from a level of 0.5 cmH(2)O/V and …
NIV-NAVA versus NCPAP immediately after birth in premature infants: A randomized controlled trial.
Lee J, Parikka V, Oda A, Wallström L, Lehtonen L, Soukka H. Lee J, et al. Respir Physiol Neurobiol. 2022 Aug;302:103916. doi: 10.1016/j.resp.2022.103916. Epub 2022 Apr 29. Respir Physiol Neurobiol. 2022. PMID: 35500883 Free article. Clinical Trial.
METHODS: Twenty infants born between 28(+0) and 31(+6) weeks were randomized to NIV-NAVA or NCPAP. Positive end-expiratory pressure was constantly kept at 6 cmH(2)O for both groups and the NAVA level was 1.0 cmH(2)O/V for NIV-NAVA group. ...However, NI …
METHODS: Twenty infants born between 28(+0) and 31(+6) weeks were randomized to NIV-NAVA or NCPAP. Positive end-expiratory pressure w …
Neurally adjusted ventilatory assist vs. pressure support to deliver protective mechanical ventilation in patients with acute respiratory distress syndrome: a randomized crossover trial.
Diniz-Silva F, Moriya HT, Alencar AM, Amato MBP, Carvalho CRR, Ferreira JC. Diniz-Silva F, et al. Ann Intensive Care. 2020 Feb 10;10(1):18. doi: 10.1186/s13613-020-0638-0. Ann Intensive Care. 2020. PMID: 32040785 Free PMC article.
For the 14 patients who completed the protocol, V(T) was 5.8 1.1 mL/kg for NAVA and 5.6 1.0 mL/kg for PSV (p = 0.455) and there were no differences in RR (24 7 for NAVA and 23 7 for PSV, p = 0.661). ...CONCLUSIONS: It was feasible to keep V(T) in prote …
For the 14 patients who completed the protocol, V(T) was 5.8 1.1 mL/kg for NAVA and 5.6 1.0 mL/kg for PSV (p = 0.455) and ther …
V-ATPase Regulates Retinal Progenitor Cell Proliferation During Eye Regrowth in Xenopus.
Kha CX, Nava I, Tseng KA. Kha CX, et al. J Ocul Pharmacol Ther. 2023 Oct;39(8):499-508. doi: 10.1089/jop.2022.0085. Epub 2023 Mar 3. J Ocul Pharmacol Ther. 2023. PMID: 36867156 Free PMC article.
Misexpression of a yeast H(+) pump was used to test whether the requirement for V-ATPase in regrowth is dependent on its H(+) pump function. Results: V-ATPase inhibition blocked eye regrowth. ...Modulation of V-ATPase activity did not affect apoptosis, a proc …
Misexpression of a yeast H(+) pump was used to test whether the requirement for V-ATPase in regrowth is dependent on its H(+) pump fu …
203 results